Shamburg News · 8-K filed Oct 1, 2026, 5:18 PM EDT
ENDRA Life Sciences Amends Merger Agreement with ASP Isotopes and Renergen Subsidiary
NDRA · ENDRA Life Sciences Inc.
- Material agreement
- Financing
- Materiality: high
On October 1, 2026, ENDRA Life Sciences entered into a First Amendment to its Agreement and Plan of Merger with ASP Isotopes, Noble Africa, Renergen and Merger Sub, among other changes revising the minimum cash closing condition to $3,800,002.59 less agreed expenses and removing the classified board requirement. The same day, ENDRA and the ASP Affiliate amended the Common and Pre-Funded Common Stock Purchase Warrants to remove the 4.99% beneficial ownership limitation. The amendment also permits increases in Renergen's borrowing capacity from ASPI from $80 million to up to $120 million, with a further contemplated increase to up to $200 million.
Source: SEC EDGAR, Form 8-K, Items 1.01, 9.01, accession 0001213900-26-105899.
Written from the filing by Shamburg Markets. Figures are as reported by the company.